These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1158 related articles for article (PubMed ID: 31903160)
1. Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive Schwenck J; Schörg B; Fiz F; Sonanini D; Forschner A; Eigentler T; Weide B; Martella M; Gonzalez-Menendez I; Campi C; Sambuceti G; Seith F; Quintanilla-Martinez L; Garbe C; Pfannenberg C; Röcken M; la Fougere C; Pichler BJ; Kneilling M Theranostics; 2020; 10(2):925-937. PubMed ID: 31903160 [No Abstract] [Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
3. Low-dose total body irradiation facilitates antitumoral Th1 immune responses. Sonanini D; Griessinger CM; Schörg BF; Knopf P; Dittmann K; Röcken M; Pichler BJ; Kneilling M Theranostics; 2021; 11(16):7700-7714. PubMed ID: 34335959 [TBL] [Abstract][Full Text] [Related]
4. Is there a link between very early changes of primary and secondary lymphoid organs in Seith F; Forschner A; Weide B; Gückel B; Schwartz M; Schwenck J; Othman AE; Fenchel M; Garbe C; Nikolaou K; Schwenzer N; la Fougère C; Pfannenberg C J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32753543 [TBL] [Abstract][Full Text] [Related]
5. Can benign lymphoid tissue changes in Sachpekidis C; Larribère L; Kopp-Schneider A; Hassel JC; Dimitrakopoulou-Strauss A Cancer Immunol Immunother; 2019 Feb; 68(2):297-303. PubMed ID: 30478475 [TBL] [Abstract][Full Text] [Related]
11. Can Baseline [ Bianchi A; De Rimini ML; Sciuto R; Annovazzi A; Di Traglia S; Bauckneht M; Lanfranchi F; Morbelli S; Nappi AG; Ferrari C; Rubini G; Panareo S; Urso L; Bartolomei M; D'Arienzo D; Valente T; Rossetti V; Caroli P; Matteucci F; Aricò D; Bombaci M; Caponnetto D; Bertagna F; Albano D; Dondi F; Gusella S; Spimpolo A; Carriere C; Balma M; Buschiazzo A; Gallicchio R; Storto G; Ruffini L; Scarlattei M; Baldari G; Cervino AR; Cuppari L; Burei M; Trifirò G; Brugola E; Zanini CA; Alessi A; Fuoco V; Seregni E; Deandreis D; Liberini V; Moreci AM; Ialuna S; Pulizzi S; Evangelista L Cancer Biother Radiopharm; 2023 May; 38(4):256-267. PubMed ID: 37098169 [No Abstract] [Full Text] [Related]
12. Relationship of FDG PET/CT imaging features with tumor immune microenvironment and prognosis in colorectal cancer: a retrospective study. Lee JW; Ahn H; Yoo ID; Hong SP; Baek MJ; Kang DH; Lee SM Cancer Imaging; 2024 Apr; 24(1):53. PubMed ID: 38627864 [TBL] [Abstract][Full Text] [Related]
13. The prognostic value of [ Sachpekidis C; Weru V; Kopp-Schneider A; Hassel JC; Dimitrakopoulou-Strauss A Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2699-2714. PubMed ID: 37099131 [TBL] [Abstract][Full Text] [Related]
15. The value of FDG PET/CT imaging in outcome prediction and response assessment of lymphoma patients treated with immunotherapy: a meta-analysis and systematic review. Kiamanesh Z; Ayati N; Sadeghi R; Hawkes E; Lee ST; Scott AM Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4661-4676. PubMed ID: 35932329 [TBL] [Abstract][Full Text] [Related]
16. Monitoring of patients with metastatic melanoma treated with immune checkpoint inhibitors using PET-CT. Dimitrakopoulou-Strauss A Cancer Immunol Immunother; 2019 May; 68(5):813-822. PubMed ID: 30123922 [TBL] [Abstract][Full Text] [Related]
17. Comparison of 18F-FDG PET/CT Criteria for the Prediction of Therapy Response and Clinical Outcome in Patients With Metastatic Melanoma Treated With Ipilimumab and PD-1 Inhibitors. Annovazzi A; Vari S; Giannarelli D; Pasqualoni R; Sciuto R; Carpano S; Cognetti F; Ferraresi V Clin Nucl Med; 2020 Mar; 45(3):187-194. PubMed ID: 31977479 [TBL] [Abstract][Full Text] [Related]
18. Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics. Seban RD; Nemer JS; Marabelle A; Yeh R; Deutsch E; Ammari S; Moya-Plana A; Mokrane FZ; Gartrell RD; Finkel G; Barker L; Bigorgne AE; Schwartz LH; Saenger Y; Robert C; Dercle L Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2298-2310. PubMed ID: 31346755 [TBL] [Abstract][Full Text] [Related]
19. Prognostic Significance of FDG Uptake of Bone Marrow on PET/CT in Patients With Non-Small-Cell Lung Cancer After Curative Surgical Resection. Lee JW; Na JO; Kang DY; Lee SY; Lee SM Clin Lung Cancer; 2017 Mar; 18(2):198-206. PubMed ID: 27495385 [TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation of [ Victorio CBL; Ong J; Tham JY; Reolo MJ; Novera W; Msallam R; Watanabe S; Kalimuddin S; Low JG; Vasudevan SG; Chacko AM Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4516-4528. PubMed ID: 35876869 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]